The role of secondary cytoreduction in low-grade serous ovarian cancer or peritoneal cancer

Gynecologic Oncology

Volumn 136, Issue 1, 2015, Pages 25-29

  Crane, Erin K ^a   Sun, Charlotte C ^a   Ramirez, Pedro T ^a   Schmeler, Kathleen M ^a   Malpica, Anais ^b   Gershensona, David M ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

Low grade serous ovarian cancer; Optimal cytoreduction; Secondary cytoreduction

Indexed keywords

ALTRETAMINE; ANASTROZOLE; BEVACIZUMAB; CARBOPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; GEMCITABINE; IFOSFAMIDE; LETROZOLE; LEUPRORELIN; NAVELBINE; PACLITAXEL; PLATINUM; TAMOXIFEN; TAXANE DERIVATIVE; TOPOTECAN;

ABSCESS; ADULT; ANASTOMOSIS LEAKAGE; ARTICLE; BACTEREMIA; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER HORMONE THERAPY; CANCER PATIENT; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CARCINOMATOUS PERITONITIS; CLINICAL ARTICLE; CYSTOTOMY; CYTOREDUCTIVE SURGERY; FEMALE; HOSPITAL READMISSION; HUMAN; INTESTINE SURGERY; MAINTENANCE THERAPY; MIDDLE AGED; MINIMAL RESIDUAL DISEASE; OPERATIVE BLOOD LOSS; OUTCOME ASSESSMENT; OVARY CANCER; OVERALL SURVIVAL; PANCREATITIS; PNEUMONIA; POSTOPERATIVE COMPLICATION; PRIMARY TUMOR; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SMALL INTESTINE OBSTRUCTION; SURGICAL INFECTION; URINARY TRACT INFECTION; WOUND INFECTION; AGED; COHORT ANALYSIS; CYSTADENOCARCINOMA, SEROUS; DISEASE FREE SURVIVAL; OVARIAN NEOPLASMS; PATHOLOGY; RETROSPECTIVE STUDY; SURVIVAL RATE; YOUNG ADULT;

ADULT; AGED; COHORT STUDIES; CYSTADENOCARCINOMA, SEROUS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM GRADING; OVARIAN NEOPLASMS; RETROSPECTIVE STUDIES; SURVIVAL RATE; YOUNG ADULT;

EID: 84925228777     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2014.11.005     Document Type: Article

References (23)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013;63(1):11-30.
2. Plaxe SC. Epidemiology of low-grade serous ovarian cancer. Am J Obstet Gynecol 2008;198(4):459.e1-8 [discussion e8-9].
3. Seidman JD, Horkayne-Szakaly I, Haiba M, Boice CR, Kurman RJ, Ronnett BM. The histologic type and stage distribution of ovarian carcinomas of surface epithelial origin. Int J Gynecol Pathol 2004;23(1):41-4.
4. Gershenson DM, Sun CC, Lu KH, Coleman RL, Sood AK, Malpica A, et al. Clinical behavior of stage II-IV low-grade serous carcinoma of the ovary. Obstet Gynecol 2006;108(2):361-8.
5. Shvartsman HS, Sun CC, Bodurka DC, Mahajan V, Crispens M, Lu KH, et al. Comparison of the clinical behavior of newly diagnosed stages II-IV low-grade serous carcinoma of the ovary with that of serous ovarian tumors of low malignant potential that recur as low-grade serous carcinoma. Gynecol Oncol 2007;105(3):625-9.
6. Singer G, Kurman RJ, Chang HW, Cho SK, Shih Ie M. Diverse tumorigenic pathways in ovarian serous carcinoma. Am J Pathol 2002;160(4):1223-8.
7. Gershenson DM. The life and times of low-grade serous carcinoma of the ovary. Am Soc Clin Oncol Educ Book 2013;2013:195-9.
8. Fader AN, Java J, Ueda S, Bristow RE, Armstrong DK, Bookman MA, et al. Survival in women with grade 1 serous ovarian carcinoma. Obstet Gynecol 2013;122(2 Pt 1):225-32.
9. Gershenson DM, Sun CC, Bodurka D, Coleman RL, Lu KH, Sood AK, et al. Recurrent low-grade serous ovarian carcinoma is relatively chemoresistant. Gynecol Oncol 2009;114(1):48-52.
10. Schmeler KM, Sun CC, Bodurka DC, Deavers MT, Malpica A, Coleman RL, et al. Neoadjuvant chemotherapy for low-grade serous carcinoma of the ovary or peritoneum. Gynecol Oncol 2008;108(3):510-4.
11. Farley J, Brady WE, Vathipadiekal V, Lankes HA, Coleman R, Morgan MA, et al. Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study. Lancet Oncol 2013;14(2):134-40.
12. Bristow RE, Puri I, Chi DS. Cytoreductive surgery for recurrent ovarian cancer: a meta-analysis. Gynecol Oncol 2009;112(1):265-74.
13. Al Rawahi T, Lopes AD, Bristow RE, Bryant A, Elattar A, Chattopadhyay S, et al. Surgical cytoreduction for recurrent epithelial ovarian cancer. Cochrane Database Syst Rev 2013;2:CD008765.
14. NCT00565851. A Phase III Randomized Controlled Clinical Trial of Carboplatin and Paclitaxel (or Gemcitabine) Alone or in Combination With Bevacizumab (NSC #704865, IND #113912) Followed by Bevacizumab and Secondary Cytoreductive Surgery in Platinum-Sensitive, Recurrent Ovarian, Peritoneal Primary and Fallopian Tube Cancer. NCI-Supplied Agents: Bevacizumab (NSC #704865, IND #113912).
15. Zang RY, Harter P, Chi DS, Sehouli J, Jiang R, Trope CG, et al. Predictors of survival in patients with recurrent ovarian cancer undergoing secondary cytoreductive surgery based on the pooled analysis of an international collaborative cohort. Br J Cancer 2011;105(7):890-6.
16. Harter P, du Bois A, Hahmann M, Hasenburg A, Burges A, Loibl S, et al. Surgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial. Ann Surg Oncol 2006;13(12):1702-10.
17. Tian WJ, Chi DS, Sehouli J, Trope CG, Jiang R, Ayhan A, et al. A risk model for secondary cytoreductive surgery in recurrent ovarian cancer: an evidence-based proposal for patient selection. Ann Surg Oncol 2012;19(2):597-604.
18. Park JY, Eom JM, Kim DY, Kim JH, Kim YM, Kim YT, et al. Secondary cytoreductive surgery in the management of platinum-sensitive recurrent epithelial ovarian cancer. J Surg Oncol 2010;101(5):418-24.
19. Bae J, Lim MC, Choi JH, Song YJ, Lee KS, Kang S, et al. Prognostic factors of secondary cytoreductive surgery for patients with recurrent epithelial ovarian cancer. J Gynecol Oncol 2009;20(2):101-6.
20. Salani R, Santillan A, Zahurak ML, Giuntoli II RL, Gardner GJ, Armstrong DK, et al. Secondary cytoreductive surgery for localized, recurrent epithelial ovarian cancer: analysis of prognostic factors and survival outcome. Cancer 2007;109(4):685-91.
21. Frederick PJ, Ramirez PT, McQuinn L, Milam MR, Weber DM, Coleman RL, et al. Preoperative factors predicting survival after secondary cytoreduction for recurrent ovarian cancer. Int J Gynecol Cancer 2011;21(5):831-6.
22. Crispens MA, Bodurka D, Deavers M, Lu K, Silva EG, Gershenson DM. Response and survival in patients with progressive or recurrent serous ovarian tumors of low malignant potential. Obstet Gynecol 2002;99(1):3-10.
23. Bristow RE, Gossett DR, Shook DR, Zahurak ML, Tomacruz RS, Armstrong DK, et al. Recurrent micropapillary serous ovarian carcinoma. Cancer 2002;95(4):791-800.